Beijing SL Pharmaceutical Co., Ltd. (SHE:002038)

China flag China · Delayed Price · Currency is CNY
5.49
0.00 (0.00%)
Jul 29, 2026, 3:04 PM CST
Market Cap5.64B -31.7%
Revenue (ttm)591.59M +1.3%
Net Income-479.28M
EPS-0.48
Shares Out 1.03B
PE Ration/a
Forward PEn/a
Dividend0.01 (0.18%)
Ex-Dividend DateJul 22, 2026
Volume30,922,807
Open5.51
Previous Close5.49
Day's Range5.43 - 5.57
52-Week Range4.81 - 9.40
Beta-0.12
Analystsn/a
Price Targetn/a
Earnings DateAug 26, 2026

About Beijing SL Pharmaceutical

Beijing SL Pharmaceutical Co., Ltd., a biopharmaceutical company, research, development, and production of genetic engineering and related drugs People’s Republic of China and internationally. The company’s finished formulations include temozolomide; arsenic trioxide; lenalidomide capsules; paclitaxel injection; docetaxel injection; thymopentin; vinorelbine tartrate injection; hydroxyl-camptothecine; nimustine hydrochloride; asparaginase; PEG L-asparaginase; calcium foliate; recombinant human basic fibroblast growth factor; liraglutide; insulin... [Read more]

Sector Healthcare
Founded 1994
Employees 901
Stock Exchange Shenzhen Stock Exchange
Ticker Symbol 002038
Full Company Profile

Financial Performance

In 2025, Beijing SL Pharmaceutical's revenue was 623.64 million, a decrease of -5.57% compared to the previous year's 660.42 million. Losses were -347.20 million, 368.8% more than in 2024.

Financial Statements